Atopic dermatitis: dupilumab shows good effectiveness in real-world study

  • Jang DH & al.
  • J Clin Med
  • 24 Jun 2020

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Dupilumab is associated with similar clinical benefits for patients with moderate to severe atopic dermatitis in the real world as in clinical trials, according to a retrospective study from Korea.

Why this matters

  • Real-world data are needed to confirm results observed in clinical trials.

Key results

  • At 16 weeks, dupilumab was associated with:
    • 77.4% improvement in the Eczema Area and Severity Index (EASI).
    • 70.0% improvement by Numerical Rating Scale.
    • 60.7% improvement in the Patient-Oriented Eczema Measure.
    • 65.0% improvement in the Dermatology Quality of Life Index.
      • P<.001 for all.>
  • At 16 weeks:
    • 92.7% of patients had achieved ≥50% improvement in EASI (EASI 50). 
    • 63.6% achieved ≥75% improvement in EASI (EASI 75).
  • Female sex was associated with good treatment response (EASI 75):
    • OR, 5.4 (P=.04).
  • Common adverse events included facial erythema (9.9%) and conjunctivitis (5.0%).

Study design

  • 101 patients with moderate to severe atopic dermatitis were treated with dupilumab for an analysis of effectiveness and safety.
  • Funding: None.

Limitations

  • Retrospective.
  • Short study duration.